Franchise Fees was Park Ha Biological Technology’s largest product and service line in fiscal 2025, bringing in $1.51M of $2.52M (60%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Franchise Fees | $937.55K | $1.81M | $1.67M | $1.51M |
| Product Sales – Franchisees | $647.42K | $346.24K | $351.40K | $478.27K |
| Products Sales – Non-Franchisees | $334.42K | $302.51K | $355.83K | $535.76K |
| Total | $1.92M | $2.46M | $2.38M | $2.52M |
Park Ha Biological Technology brought in $2.52M from its three product and service lines in fiscal 2025, the year ended October 31, 2025. That was up 6.0% from $2.38M in fiscal 2024. Franchise Fees was the largest at $1.51M (59.8%), ahead of Products Sales – Non-Franchisees at $535.76K (21.2%) and Product Sales – Franchisees at $478.27K (18.9%).
Compared with fiscal 2024, Products Sales – Non-Franchisees grew fastest, up 50.6% to $535.76K, while Franchise Fees fell the most, down 9.8% to $1.51M. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.92M to $2.52M, a compound annual growth rate of 9.6%. Franchise Fees' share of the total rose from 48.8% to 59.8%.
Franchise Fees was Park Ha Biological Technology’s largest segment in fiscal 2025, bringing in $1.51M of $2.52M (60%).
| Segment | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Franchise Fees | $937.55K | $1.81M | $1.67M | $1.51M |
| Product Sales | $981.84K | $648.75K | $707.23K | $1.01M |
| Total | $1.92M | $2.46M | $2.38M | $2.52M |
Park Ha Biological Technology brought in $2.52M from its two segments in fiscal 2025, the year ended October 31, 2025. That was up 6.0% from $2.38M in fiscal 2024. Franchise Fees was the largest at $1.51M (59.8%), ahead of Product Sales at $1.01M (40.2%).
Compared with fiscal 2024, Product Sales grew 43.4% to $1.01M, while Franchise Fees fell 9.8% to $1.51M. From fiscal 2022 to 2025, combined revenue from these segments grew from $1.92M to $2.52M, a compound annual growth rate of 9.6%. Franchise Fees' share of the total rose from 48.8% to 59.8%.
Park Ha Biological Technology (BYAH) reports its revenue by product and service and by segment. In fiscal 2025, Franchise Fees was its largest product and service line, bringing in $1.51M (59.8% of the total), followed by Products Sales – Non-Franchisees at $535.76K (21.2%).
Franchise Fees was Park Ha Biological Technology's largest product and service line in fiscal 2025, bringing in $1.51M, or 59.8% of the $2.52M total across its three product and service lines.
Franchise Fees was Park Ha Biological Technology's largest segment in fiscal 2025, bringing in $1.51M, or 59.8% of the $2.52M total across its two segments.
Among Park Ha Biological Technology's product and service lines that make up at least 2% of revenue, Products Sales – Non-Franchisees grew fastest in fiscal 2025, up 50.6% from $355.83K to $535.76K.
Every figure comes from Park Ha Biological Technology's annual financial filings, as reported. Each line keeps the name Park Ha Biological Technology gives it, and years follow its fiscal calendar.
Park Ha Biological Technology's revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.